4-Year Follow-Up After Transcatheter Tricuspid Valve Replacement Using the EVOQUE System

Lukas Stolz; Thomas J Stocker; Ludwig T Weckbach; Simon Schmid; Julia Novotny; Philipp M Doldi; Steffen Massberg; Michael Näbauer; Jörg Hausleiter

doi:10.1016/j.jaccas.2024.102393

4-Year Follow-Up After Transcatheter Tricuspid Valve Replacement Using the EVOQUE System

JACC Case Rep. 2024 Jun 13;29(14):102393. doi: 10.1016/j.jaccas.2024.102393. eCollection 2024 Jul 17.

Authors

Lukas Stolz¹, Thomas J Stocker^{1

2}, Ludwig T Weckbach^{1

2}, Simon Schmid¹, Julia Novotny¹, Philipp M Doldi¹, Steffen Massberg^{1

2}, Michael Näbauer^{1

2}, Jörg Hausleiter^{1

2}

Affiliations

¹ Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Munich, Germany.
² German Center for Cardiovascular Research, Partner Site Munich Heart Alliance, Munich, Germany.

Abstract

Transcatheter tricuspid valve replacement (TTVR) is an increasingly used treatment technique for patients with severe tricuspid regurgitation (TR). Currently, available data from international registries and randomized controlled trials provide outcome data until a maximum follow-up of 2 years after the procedure. This case report presents 4-year follow-up data for an 84-year-old woman who underwent TTVR for torrential TR in 2019. The patient experienced durable TR reduction, symptomatic improvement, right ventricular reverse remodeling, and substantial improvement in liver and kidney function.

Keywords: EVOQUE; TTVR; long-term follow-up; transcatheter tricuspid valve replacement; tricuspid regurgitation.

Publication types

Case Reports